Breaking News, Trials & Filings

Trials & Filings in Brief: Oct. 8, 2013

Acorda, Alkermes, Alnylam, Cornerstone, Eleison, and Keryx

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Preclinical Alnylam advances ALAS-1 attacker . . . read more Phase I Acorda begins second HF trial of GGF2 . . . read more Phase III Alkermes completes patient enrollment . . . read more Filings Cornerstone MDS drug gets orphan status . . . read more Eleison gets orphan status from EC for osteosarcoma treatment . . . read more FDA Accepts Keryx NDA for Zerenex . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters